Biotech Decliners: Recro Pharma Inc (NASDAQ:REPH), Ignyta Inc (NASDAQ:RXDX), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aegis started coverage on shares of Recro Pharma Inc. (NASDAQ:REPH) in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $40.00 price target on the stock. Aegis’ price objective suggests a potential upside of 412.16% from the company’s current price. Recro Pharma Inc (NASDAQ:REPH) stock performance was -7.30% in last session and finished the day at $7.24. Traded … Continue reading Biotech Decliners: Recro Pharma Inc (NASDAQ:REPH), Ignyta Inc (NASDAQ:RXDX), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Healthcare losers: Corcept Therapeutics Incorporated (NASDAQ:CORT), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Anika Therapeutics (NASDAQ:ANIK), Oncomed Pharmaceuticals (NASDAQ:OMED), Cesca Therapeutics (NASDAQ:KOOL)

Corcept Therapeutics Inc (NASDAQ:CORT) Director G Leonard Baker, Jr. bought 103,386 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was purchased at an average cost of $2.32 per share, for a total transaction of $239,855.52. Following the completion of the transaction, the director now directly owns 578,389 shares of the company’s stock, valued at approximately $1,341,862. Corcept Therapeutics … Continue reading Healthcare losers: Corcept Therapeutics Incorporated (NASDAQ:CORT), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Anika Therapeutics (NASDAQ:ANIK), Oncomed Pharmaceuticals (NASDAQ:OMED), Cesca Therapeutics (NASDAQ:KOOL)

Seattle Genetics, Inc (NASDAQ:SGEN) Director Felix Baker purchased 281,963 shares of Seattle Genetics stock in a transaction dated Wednesday, June 4th. The stock was purchased at an average price of $34.86 per share, for a total transaction of $9,829,230.18. Following the transaction, the director now directly owns 76,997 shares of the company’s stock, valued at approximately $2,684,115. Seattle Genetics, Inc. (NASDAQ:SGEN) stock performance was -0.05% … Continue reading Biotech Insider Buying: Seattle Genetics (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Cytori Therapeutics (NASDAQ:CYTX), Oramed Pharmaceuticals (NASDAQ:ORMP), Biota Pharmaceuticals (NASDAQ:BOTA)

Bazaarvoice Inc (NYSE:BV) President Eugene Austin purchased 10,000 shares of the company’s stock on the open market in a transaction dated Monday, June 9th. The stock was purchased at an average price of $7.05 per share, with a total value of $70,500.00. Following the acquisition, the president now directly owns 260,000 shares in the company, valued at approximately $1,833,000. Bazaarvoice Inc (NASDAQ:BV) stock performance was … Continue reading NASDAQ Insider Buying: Bazaarvoice Inc (NASDAQ:BV), Seattle Genetics (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Career Education (NASDAQ:CECO), Acorn Energy (NASDAQ:ACFN)

A Palo Alto startup will focus an $18 million VC investment on developing a drug to stop unexplained recurrent miscarriages. Nora Therapeutics is capitalizing on work started by cofounder Darryl Carter at Johns Hopkins University that led to development of Nora’s lead drug, NT-100. Nora is led by CEO Jeff Tong, who had been vice president of corporate and product development at Infinity Pharmaceuticals Inc. … Continue reading Biotech Bearish Stocks: Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Corcept Therapeutics Incorporated (NASDAQ:CORT), Puma Biotechnology Inc (NYSE:PBYI), Conatus Pharmaceuticals (NASDAQ:CNAT)

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), just announced a positive, top-line result in a Phase 2 clinical trial of their experimental therapy LX4211 in type 1 diabetes. LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2, was designed to lower blood glucose levels through two insulin-independent mechanisms of action. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock performance was 5.16% in last session and finished the … Continue reading Biotech Volatile Stocks: Lexicon Pharmaceuticals (NASDAQ:LXRX), Corcept Therapeutics Incorporated (NASDAQ:CORT), Insys Therapeutics (NASDAQ:INSY), ANI Pharmaceuticals (NASDAQ:ANIP)